AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $54.64.

A number of equities research analysts have issued reports on ANAB shares. Guggenheim boosted their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a report on Monday, October 21st. UBS Group boosted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. HC Wainwright reduced their price target on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Truist Financial boosted their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Finally, Wedbush restated an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research report on Thursday, November 14th.

AnaptysBio Stock Up 5.2 %

AnaptysBio stock opened at $22.27 on Friday. The stock has a market cap of $677.68 million, a P/E ratio of -3.66 and a beta of -0.24. The company’s 50 day moving average price is $29.42 and its two-hundred day moving average price is $29.69. AnaptysBio has a 52 week low of $13.36 and a 52 week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. On average, equities analysts anticipate that AnaptysBio will post -6.02 EPS for the current year.

Insider Buying and Selling

In related news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at $189,333.04. This represents a 72.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This trade represents a 8.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock valued at $892,936 over the last three months. Corporate insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

A number of hedge funds and other institutional investors have recently bought and sold shares of ANAB. Allspring Global Investments Holdings LLC purchased a new stake in AnaptysBio in the first quarter worth about $38,000. Values First Advisors Inc. purchased a new stake in AnaptysBio in the third quarter worth about $49,000. nVerses Capital LLC grew its holdings in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares during the period. Headlands Technologies LLC grew its holdings in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 2,600 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.